The Corporate Reputation of Pharma 2015 - The Perspective of 199 Patient Groups with an Interest in Rare Diseases

  • ID: 3942639
  • Report
  • 60 pages
  • PatientView
1 of 4

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Boehringer Ingelheim
  • GSK
  • Merck & Co
  • Pfizer
  • MORE

This report is based on the findings of a November 2015-January 2016 survey exploring the views of 199 patient groups with an interest in rare diseases worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 28 pharma companies for six key indicators that influence corporate reputation. Results are compared with those of the previous year.

“Dans notre domaine de maladies rares où des efforts ont été faits pour impliquer les patients.” (“In our field of rare diseases, efforts have been made to involve patients.”) 

—National France-based patient group specialising in rare neurological diseases      

Profiles Of the 28 Companies, According To the Neurological Patient Groups Familiar with These Companies, or Have Worked With Them

Each profile contains

Company Background Information

  •     Annual revenue (latest-available year), comprising amount in currency, as quoted by the profiled company itself. Increase in revenue over the previous year or decrease in revenue.
  •     The profiled company’s main treatment subject areas (and areas of R&D).
  •     A mission statement from the profiled company.

How the Company Has Performed At Six Indicators of Corporate Reputation

  •  The profiled company’s performance at the six indicators of corporate reputation in 2015, according to the neurological patient groups familiar with the company.
  •  The profiled company’s performance at the six indicators of corporate reputation, according to the neurological patient groups that have worked with the company.
  •  How the profiled company performed among neurological patient groups for different countries/regions, compared with the company’s global averages for neurological patient groups in 2015.

How the Company Ranks For Corporate Reputation Compared With Other Companies

  •  The profiled company’s rankings among neurological patient groups in 2015 for the six indicators of corporate reputation, compared with 27 other companies.
  •  The profiled company’s rankings worldwide in 2015 for the six indicators of corporate reputation, compared with 47 other companies.

Profile of The Patient Groups Familiar With The Company

  •  Other companies that partner with a significant number of the profiled company’s partner patient groups.
  •  The countries of the patient groups familiar with the profiled company.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Boehringer Ingelheim
  • GSK
  • Merck & Co
  • Pfizer
  • MORE

ABOUT THIS REPORT 

WHAT DID RARE-DISEASE PATIENT GROUPS SAY ABOUT PHARMA IN 2015?
 Summary of the industry-wide findings (as judged by rare-disease patient groups)

A FEW COMMENTS ON THE RARE-DISEASE CORPORATE RANKINGS 

WHAT CAN PHARMA COMPANIES DO TO IMPROVE THEIR CORPORATE REPUTATION?

COMMENTS FROM RARE-DISEASE PATIENT GROUPS, 2015 

METHODOLOGY OF THE PATIENT-GROUP SURVEY 

APPENDIX 1:  Data on how rare-disease patient groups see the pharmaceutical industry in 2015
APPENDIX 2:  Rankings of the 28 pharma companies for each of the 6 indicators of corporate reputation, as perceived by rare-disease patient groups in 20
APPENDIX 3:  Profiles of the 28 companies
APPENDIX 4:  Profiles of the 199 respondent rare-disease patient groups

LIST OF TABLES AND CHARTS—BASED ON THE VIEWS OF RARE-DISEASE PATIENT GROUPS, 2015
 Percentage of rare-disease patient groups claiming familiarity with the company 
 Percentage of rare-disease patient groups claiming familiarity with the company, and which also worked with it  
 Percentage of patient groups worldwide (by therapy area) stating that pharma is “Excellent” or “Good” at PROVIDING HIGH-QUALITY, USEFUL PRODUCTS
 Percentage of patient groups worldwide (by therapy area) stating that pharma is “Excellent” or “Good” at PATIENT SAFETY
 Top-ten pharma companies 2015, according to patient groups specialising in rare diseases (v. rare diseases ranking, 2014)
 If a pharma company wishes to improve its corporate reputation with patients and patient groups, which single strategy from the list below do you think would be MOST IMPORTANT for the company to follow? Please select only ONE option
 How do you think your organisation’s members (or the people you represent) would rate the corporate reputation of the following healthcare sectors in 2015?
 What do you think has happened to the corporate reputation of the pharma industry over the past five years? 
 How good or bad do you think the pharma industry is in 2015 at carrying out the following activities (all of which influence their corporate standing with patients and patient groups)?
 How good or bad do you think the pharma industry is in 2015 at carrying out the following activities (all of which influence their corporate standing with patients and patient groups)?
Companies with the most effective PATIENT-CENTRED STRATEGY (rankings of 28 companies, 2015) 
Companies providing the best HIGH-QUALITY PATIENT INFORMATION (rankings of 28 companies, 2015) 
Companies with the best record on PATIENT SAFETY (rankings of 28 companies, 2015) 
Companies with the most-useful HIGH-QUALITY PRODUCTS (rankings of 28 companies, 2015) 
Companies with the best record of TRANSPARENCY (rankings of 28 companies, 2015) 
Companies with the best record on INTEGRITY (rankings of 28 companies, 2015) 
Rankings of the 28 pharmaceutical companies in 2015, alphabetic order 
Rankings of the 28 pharmaceutical companies in 2015, highest to lowest 
Geographic headquarters of 2015’s 199 respondent rare-disease patient groups—by country 
Geographic remit of 2015’s 199 respondent rare-disease patient groups

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie
  • Actavis
  • Allergan
  • Amgen
  • AstraZeneca
  • Baxalta
  • Bayer
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Gilead
  • GSK
  • Janssen
  • Lilly
  • Lundbeck
  • Merck & Co
  • Merck KGaA
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Roche
  • Sandoz
  • Sanofi
  • Shire
  • Takeda
  • Teva
  • UCB
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll